NCT06603220 is a Phase 2 clinical trial of Oral EVO756 in Chronic Inducible Urticaria, sponsored by Evommune, Inc..

Who is sponsoring NCT06603220?

NCT06603220 is sponsored by Evommune, Inc..

What drugs are being tested in NCT06603220?

Interventions in NCT06603220: Oral EVO756.

What condition does NCT06603220 study?

NCT06603220 studies Chronic Inducible Urticaria.

Is NCT06603220 still recruiting?

NCT06603220 is currently completed. Last updated 18 June 2025.

Last reviewed 2025-06-18 · How we verify

NCT06603220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Completed Phase 2 Last updated 18 June 2025

What this trial tests

Phase 2 trial testing Oral EVO756 in Chronic Inducible Urticaria in 30 participants. Completed in 8 May 2025.

Timeline

14 August 2024

Primary endpoint
8 May 2025

8 May 2025

Quick facts

Lead sponsor	Evommune, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	14 August 2024
Primary completion	8 May 2025
Estimated completion	8 May 2025
Sites	18 locations across United States

Drugs / interventions tested

Oral EVO756 — full drug profile →

Conditions studied

Chronic Inducible Urticaria — all drugs for Chronic Inducible Urticaria →

Sponsor

Evommune, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Inducible Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment.
Tbakhi B, Ware K, Park HS, Bernstein JS, et al · · 2025 · cited 2× · PMID 41044830 · DOI 10.4168/aair.2025.17.5.531
Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond.
Hsu FI, Bernstein JA, Chhiba KD, Saini SS. · · 2026 · cited 1× · PMID 41654334 · DOI 10.1016/j.jaip.2025.11.038
Emerging IgE and non-IgE targeted therapies for chronic urticaria.
Chhiba KD, Saini SS. · · 2026 · cited 1× · PMID 41270830 · DOI 10.1016/j.anai.2025.11.008
Advancements and challenges in the management of chronic inducible urticaria.
Zhang M, Liu J, Zhi Y. · · 2026 · PMID 42112401 · DOI 10.3389/fimmu.2026.1747542
Neuro-immune interactions in urticaria:a pruritus-centric dissection
Ke C, Ma N, Chen G, Yao Y, et al ·
Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms.
Türk M, Bizjak-Suran M, Can PK, Criado PR, et al · · 2026 · PMID 41960557 · DOI 10.5415/apallergy.0000000000000279

Verify or expand the search:

Other recruiting trials for Chronic Inducible Urticaria

Currently open trials in the same condition.

NCT06931405 — Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) · Phase 2 · recruiting
NCT05976243 — A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Ina · Phase 3 · active not recruiting

Other Evommune, Inc. trials

Trials by the same sponsor.

NCT06723405 — Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis · Phase 2 · completed
NCT05579899 — Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06603220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Evommune, Inc.
Last refreshed: 18 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06603220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing